EsoCap AG
(‘EsoCap’) is offering an equity investment of CHF 10 million in a private
placement at CHF 28 per share, representing a pre-money valuation of
CHF 77.5 million.
The funds
from this offering will be used to roll out the international patent portfolio, prepare the pivotal Phase III clinical trial, interact with regulatory authorities in the US and Europe, scale up industrially, and produce clinical trial material.
EsoCap is in the process of preparing a commercial transaction with a major pharmaceutical company specialising in gastroenterology and cancer. The goal is a trade sale projected at around 300m CHF.
About EsoCap
EsoCap AG is a
privately funded joint stock company based in Basel, Switzerland.
EsoCap has
successfully developed a unique, highly sophisticated platform technology with
multiple applications for local drug therapy in patients with severe
oesophageal diseases.
EsoCaps technology
guarantees a significantly longer contact time of drugs (small molecules,
peptides, biologics, and encapsulated mRNA treatment principles) in the
oesophagus, resulting in a safe and highly effective treatment outcome.
The lead candidate
ESO-101 has received Orphan Drug Designation from the US Food & Drug
Administration (FDA) for the treatment of eosinophilic oesophagitis (EoE).
EsoCap recently successfully completed the double-blind, randomised,
placebo-controlled Phase II ACESO study with ESO-101 in five countries,
demonstrating the clinical applicability of the platform technology.
EsoCap has a strong
and diversified intellectual property position as well as a highly
complementary team and development infrastructure.
For more information,
please visit www.esocapbiotech.com and follow EsoCap on LinkedIn and Twitter.
Contact:
Isabelle Racamier
CEO
isabelle.racamier@esocapbiotech.com
Phone: +43 699 149 50 300
Privately held , founded in 2017
1 - 5 employees
Investment service provider